Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-19 in Pediatric R/R CD19+ B-cell Malignancies
NCT06393335Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-19 in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 3 months. Started May 2024; status: recruiting.
02
Drugs
Meta10-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06393335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393335.